Calton & Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Calton & Associates’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-300	Closed	-$25K	–	1507
2017 Q4	$25K	Buy	+300	New	+$15K	0.01%	851

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Calton & Associates's JUNO Position: Q1 2018 in Review

Calton & Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 300 shares — an estimated $25K sold.

Calton & Associates first reported a position in JUNO in Q4 2017 and held it in 1 quarter. The position peaked at $25K in Q4 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

Calton & Associates reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Calton & Associates sold 300 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $25K.
Calton & Associates first reported a position in Juno Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
Calton & Associates's Juno Therapeutics, Inc. position peaked at $25K in Q4 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Calton & Associates's 13F filing for Q1 2018, filed 17 Apr 2018.